Efineptakin alfa for opportunistic infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Nov 2022: Trial registered, NCT05600920
  2. 6 Nov 2024: Trial started, NCT05600920

The trials

NCT05600920: A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia

State
Under way
Phase
Phase 1 and Phase 2
People
60 planned
Started
6 Nov 2024
Primary completion
1 Nov 2026
Arms
Single Cohort
Results
None posted
  1. 1 Nov 2022: Trial registered
  2. 6 Nov 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Hyleukin, Recombinant human interleukin (IL) 7-hyFc.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.